Literature DB >> 11000004

Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.

J D Tyndall1, R C Reid, D P Tyssen, D K Jardine, B Todd, M Passmore, D R March, L K Pattenden, D A Bergman, D Alewood, S H Hu, P F Alewood, C J Birch, J L Martin, D P Fairlie.   

Abstract

Three new peptidomimetics (1-3) have been developed with highly stable and conformationally constrained macrocyclic components that replace tripeptide segments of protease substrates. Each compound inhibits both HIV-1 protease and viral replication (HIV-1, HIV-2) at nanomolar concentrations without cytotoxicity to uninfected cells below 10 microM. Their activities against HIV-1 protease (K(i) 1.7 nM (1), 0.6 nM (2), 0.3 nM (3)) are 1-2 orders of magnitude greater than their antiviral potencies against HIV-1-infected primary peripheral blood mononuclear cells (IC(50) 45 nM (1), 56 nM (2), 95 nM (3)) or HIV-1-infected MT2 cells (IC(50) 90 nM (1), 60 nM (2)), suggesting suboptimal cellular uptake. However their antiviral potencies are similar to those of indinavir and amprenavir under identical conditions. There were significant differences in their capacities to inhibit the replication of HIV-1 and HIV-2 in infected MT2 cells, 1 being ineffective against HIV-2 while 2 was equally effective against both virus types. Evidence is presented that 1 and 2 inhibit cleavage of the HIV-1 structural protein precursor Pr55(gag) to p24 in virions derived from chronically infected cells, consistent with inhibition of the viral protease in cells. Crystal structures refined to 1.75 A (1) and 1.85 A (2) for two of the macrocyclic inhibitors bound to HIV-1 protease establish structural mimicry of the tripeptides that the cycles were designed to imitate. Structural comparisons between protease-bound macrocyclic inhibitors, VX478 (amprenavir), and L-735,524 (indinavir) show that their common acyclic components share the same space in the active site of the enzyme and make identical interactions with enzyme residues. This substrate-mimicking minimalist approach to drug design could have benefits in the context of viral resistance, since mutations which induce inhibitor resistance may also be those which prevent substrate processing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000004     DOI: 10.1021/jm000013n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Inhibition and substrate recognition--a computational approach applied to HIV protease.

Authors:  H M Vinkers; M R de Jonge; E D Daeyaert; J Heeres; L M H Koymans; J H van Lenthe; P J Lewi; H Timmerman; P A J Janssen
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

2.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction.

Authors:  Alessia Bellomaria; Gaetano Barbato; Gerry Melino; Maurizio Paci; Sonia Melino
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

4.  Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.

Authors:  Adel A Rashad; Ramalingam Venkat Kalyana Sundaram; Rachna Aneja; Caitlin Duffy; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

5.  Analysis of structural water and CH···π interactions in HIV-1 protease and PTP1B complexes using a hydrogen bond prediction tool, HBPredicT.

Authors:  Joshy P Yesudas; Fareed Bhasha Sayyed; Cherumuttathu H Suresh
Journal:  J Mol Model       Date:  2010-05-19       Impact factor: 1.810

6.  Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach.

Authors:  E Prabhu Raman; Wenbo Yu; Sirish K Lakkaraju; Alexander D MacKerell
Journal:  J Chem Inf Model       Date:  2013-11-25       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.